October 7, 2020 | technology | No Comments
Codiak BioSciences (CDAK) has filed to raise $82.5 million from the sale of its common stock in an IPO, according to an amended registration statement.
Cambridge, Massachusetts-based Codiak Biosciences was founded in 2015 to develop new exosome-based allogeneic therapies – “therapies derived from human cells that can be used in any patient.”
Management is headed by President, CEO and Director Douglas E. Williams, who has been with the firm since its inception and was previously Executive Vice President Research and Development at Biogen.
Codiak has developed the engEx Platform, a proprietary platform for the engineering and manufacturing of exosomes with “intentionally chosen properties, to incorporate various types of biologically active molecules, including small molecules, nucleic acids, proteins, antibodies, enzymes, cytokines and complex ligands, and to be directed to specific cell types and tissues.”
Management believes engEx to be easily expandable to support siRNA, miRNA, mRNA, ASO and CRISPR, “to engage